These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34249409)

  • 1. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.
    Huang Q; Cai WQ; Han ZW; Wang MY; Zhou Y; Cheng JT; Zhang Y; Wang YY; Xin Q; Wang XW; Peng XC; Xiang Y; Fang SX; Ma ZW; Xin HY; Cui SZ; Xin HW
    Am J Cancer Res; 2021; 11(6):2430-2455. PubMed ID: 34249409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer.
    Liu S; Li F; Deng L; Ma Q; Lu W; Zhao Z; Liu H; Zhou Y; Hu M; Wang H; Yan Y; Zhao M; Zhang H; Du M
    Mol Ther Oncolytics; 2023 Sep; 30():275-285. PubMed ID: 37701851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
    Heidbuechel JPW; Engeland CE
    J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
    Scott EM; Duffy MR; Freedman JD; Fisher KD; Seymour LW
    Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28902983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
    Guo ZS; Lotze MT; Zhu Z; Storkus WJ; Song XT
    Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32664210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status.
    Wang Y; Cheng P
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166962. PubMed ID: 37984801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
    Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
    Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
    Nguyen HM; Guz-Montgomery K; Saha D
    Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
    Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
    EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are BiTEs the "missing link" in cancer therapy?
    Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
    Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors.
    Wei M; Zuo S; Chen Z; Qian P; Zhang Y; Kong L; Gao H; Wei J; Dong J
    Front Immunol; 2022; 13():1017574. PubMed ID: 36451817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus therapy for malignant gliomas: entering the new era.
    Fudaba H; Wakimoto H
    Expert Opin Biol Ther; 2023 Mar; 23(3):269-282. PubMed ID: 36809883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.